Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Open access
Schettini, Francesco, Pascual, Tomás, Conte, Benedetta, Chic, Nuria, Brasó-Maristany, Fara, Galván, Patricia, Martínez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernández-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco, Locci, Mariavittoria, Brase, Jan C., Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Veeraraghavan, Jamunarani, Rimawi, Mothaffar F., Osborne, C. Kent, Pernas, Sonia, Perou, Charles M., Carey, Lisa A., Prat, Aleix · 2020 · Cancer Treatment Reviews

Abstract

Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-E appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based regimens. Here, we present a meta-analysis to validate the association of the HER2-E subtype with pCR following anti-HER2-based neoadjuvant treatments with or without chemotherapy (CT). Methods: A systematic literature search was performed in February 2019. The primary objective was to compare the association between HER2-E subtype (versus others) and pCR. Selected secondary objectives were to compare the association between 1) HER2-E subtype and pCR in CT-free studies, 2) HER2-E subtype within hormone receptor (HR)-negative and HR+ disease and 3) HR-negative disease (versus HR+) and pCR in all patients and within HER2-E subtype. A random-effect model was applied. The Higgins’ I2 was used to quantify heterogeneity. Results: Sixteen studies were included, 5 of which tested CT-free regimens. HER2-E subtype was significantly associated with pCR in all patients (odds ratio [OR]=3.50, p<0.001, I2=33%), in HR+ (OR=3.61, p<0.001, I2=1%) and HR-negative tumors (OR=2.28, p=0.01, I2=47%). In CT-free studies, HER2-E subtype was associated with pCR in all patients (OR=5.52, p<0.001, I2=0%) and in HR+ disease (OR=4.08, p=0.001, I2=0%). HR-negative status was significantly associated with pCR compared to HR+ status in all patients (OR=2.41, p<0.001, I2=30%) and within the HER2-E subtype (OR=1.76, p<0.001, I2=0%). Conclusions: The HER2-E biomarker identifies patients with a higher likelihood of achieving a pCR following neoadjuvant anti-HER2-based therapy beyond HR status and CT use. Future trial designs to escalate or de-escalate systemic therapy in HER2+ disease should consider this genomic biomarker.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ctrv.2020.101965

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 178

Metadata

Authors
Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó-Maristany, F., Galván, P., Martínez, O., Adamo, B., Vidal, M., Muñoz, M., Fernández-Martinez, A., Rognoni, C., Griguolo, G., Guarneri, V., Conte, P. F., Locci, M., Brase, J. C., Gonzalez-Farre, B., Villagrasa, P., De Placido, S., Schiff, R., Veeraraghavan, J., Rimawi, M. F., Osborne, C. K., Pernas, S., Perou, C. M., Carey, L. A., & Prat, A.
Venue
Cancer Treatment Reviews
Publisher
Elsevier BV
Published
2020-03
Volume
84
Pages
101965
ISSN
0305-7372 (ISSN-L)
OpenAlex
W2998950563
Cited by
178
References
7
FWCI
3.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/j.ctrv.2020.101965
The paper
Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó-Maristany, F., Galván, P., Martínez, O., Adamo, B., Vidal, M., Muñoz, M., Fernández-Martinez, A., Rognoni, C., Griguolo, G., Guarneri, V., Conte, P. F., Locci, M., Brase, J. C., Gonzalez-Farre, B., Villagrasa, P., . . . Prat, A. (2020). HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2020.101965

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.